The purpose of this study is to provide a central mechanism for monitoring access to peripheral blood, urine, and skin specimens obtained from CTCL, eczema, and atopic dermatitis patients to monitor:
* immunologic assays/flow cytometry
* tumor progression/regression
* genomic studies
* proteomic studies
* others germane to the advancement of CTCL treatment
